IL-1beta regulates cellular proliferation, prostaglandin E2 synthesis, plasminogen activator activity, osteocalcin production, and bone resorptive activity of the mouse calvarial bone cells.
Interleukin-1beta (IL-1beta) regulates several activities of the osteoblast cells derived from mouse calvarial bone explants in vitro. IL-1beta stimulated cellular proliferation and the synthesis of prostaglandin E2 in the cultured cells in a dose-dependent manner. Furthermore, plasminogen activator activity of the mouse osteoblast was positively affected by IL-1beta in a dose-dependent manner over the dosage range of 0.01 ng-2 ng/mL with a maximal effect being observed at 2 ng/mL. However, the induction of osteocalcin synthesis and alkaline phosphatase activity in response to vitamin D, two characteristics of the osteoblast phenotype, were significantly antagonized by IL-1beta over a similar dose range. Treatment of mouse calvarial bone cells with IL-1beta resulted in a dose dependent stimulation of bone resorption and the bone resorption induced by IL-1beta was strongly inhibited by calcitonin treatment, indicating osteoclast-mediated bone resorption, suggesting that the bone resorption induced by IL-1beta appears to be osteoclast-mediated. This study supports the role of IL-1beta in the pathological modulation of bone cell metabolism, with regard to implication of the pathogenesis of osteoporosis by IL-1beta.
Kim
Cheorl-Ho
CH
Department of Biochemistry and Molecular Biology, College of Oriental Medicine, Dongguk University, Kyungju City, Kyungbuk, Korea. chkimbio@dongguk.ac.kr
Kang
Bong-Seok
BS
Lee
Tae-Kyun
TK
Park
Won-Hwan
WH
Kim
June-Ki
JK
Park
Young-Guk
YG
Kim
Hyung-Min
HM
Lee
Young-Choon
YC
D000818:Animals; D001862:Bone Resorption / Q000139:chemically induced*; D002116:Calcitonin / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D015232:Dinoprostone / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D007375:Interleukin-1 / Q000494:pharmacology*; D051379:Mice; D010006:Osteoblasts / Q000187:drug effects* / Q000502:physiology; D015675:Osteocalcin / Q000096:biosynthesis*; D010960:Plasminogen Activators / Q000032:analysis*; D012886:Skull; D014807:Vitamin D / Q000494:pharmacology
D007375:Interleukin-1; D015675:Osteocalcin; D014807:Vitamin D; D002116:Calcitonin; D010960:Plasminogen Activators; D015232:Dinoprostone